{"id":"W4408500171","doi":"10.1002/ejhf.3642","title":"How to Handle Polypharmacy in Heart Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC","year":2025,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"Biosense Webster; Servier; University of Glasgow; European Commission; Vifor Pharma; Pfizer; LivaNova; Boston Scientific Corporation; Amgen; Edwards Lifesciences; Alnylam Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; Bayer; Intas Pharmaceuticals; AstraZeneca; Idorsia Pharmaceuticals; British Heart Foundation; Cytokinetics; Abbott Vascular; Abbott Laboratories","keywords":"Polypharmacy; Medicine; Heart failure; Intensive care medicine; Tolerability; Medical prescription; Adverse effect; Drug; Quality of life (healthcare); Internal medicine; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005859466,0.001095934,0.002244434,0.002944762,0.000455584,0.001913252,0.001908471,0.004274353,0.003299815],"category_scores_gemma":[0.007181381,0.0004634625,0.002155976,0.001855918,0.0005771467,0.002257366,0.001443294,0.00362862,0.002672006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001198348,"about_ca_system_score_gemma":0.005207697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003438717,"about_ca_topic_score_gemma":0.00608559,"domain_scores_codex":[0.997891,0.0006003984,0.0004884566,0.0001299434,0.0007676327,0.0001226354],"domain_scores_gemma":[0.9968913,0.001120356,0.0004386539,0.00007672408,0.001237256,0.0002357631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006519324,0.0001029242,0.0002307794,0.02790694,0.0002474195,0.0001355362,0.0001042557,0.0002397272,0.0004230906,0.003394426,0.1332367,0.8339131],"study_design_scores_gemma":[0.00009227704,0.00008544369,0.001408784,0.04627698,0.0003084511,0.0005423653,0.00009818401,0.0001409992,0.0001753308,0.003389743,0.947454,0.000027514],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001292495,0.9792787,0.0006393287,0.01489759,0.002327262,0.0001196974,0.0001146534,0.00002836755,0.002465297],"genre_scores_gemma":[0.001618796,0.9833897,0.002858624,0.008663274,0.001192128,0.0001809636,0.0002871818,0.00001217081,0.001797104],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005859466,"threshold_uncertainty_score":0.03098816,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04278002057642017,"score_gpt":0.3557567067224014,"score_spread":0.3129766861459812,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}